Skip to main content

MoneyWorks4Me

Mahamaya Lifesciences informs about disclosure

10 Mar 2026 Evaluate
Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, Mahamaya Lifesciences has informed that the Board of Directors of the Company, through a circular resolution passed on 10th March 2026, has approved the utilisation of the unutilised Initial Public Offer (IPO) proceeds in subsequent fiscal years i.e., up to March 31, 2028, in a phased manner.

The above information is a part of company’s filings submitted to BSE.
Peers
Company Name CMP
UPL 528.50
PI Industries 2186.80
Bayer CropScience 3249.85
Sharda Cropchem 678.60
Sumitomo Chem. India 327.95
View more..